source
- Odyssey, on second try, snags $279M in an IPOAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…BioPharma Dive · 3mo ago↗ source
- Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study foundSTAT · 3mo ago↗ source
- Astellas touts data from early test of stem cell-derived eye therapyAstellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The e…